Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study

Objective To test the hypothesis that low density lipoprotein (LDL) cholesterol due to genetic variation in the genes responsible for LDL cholesterol metabolism and biosynthesis(PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), respectively) is associated with a high risk of Alzheimer's disease, vascular dementia, any dementia, and Parkinson's disease in the general population.Design ...

متن کامل

Low LDL-cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s dementia and Parkinson’s disease: a Mendelian randomization study

1 Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark; 2 The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark; 3 The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Denmark; 4 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen Univers...

متن کامل

Prevalence of Peripheral Arterial Disease in Diabetic Patients

Objective: Peripheral Arterial Disease (PAD) is a state characterized by atherosclerotic occlusive disease of lower extremities. Diabetes is the main risk factor for PAD. Material and Methods: To assess the prevalence of PAD, a cross sectional study was performed on 352 diabetic patients who referred to Yazd diabetes research center from 2007 to 2010. Vascular assessment was done by measuring ...

متن کامل

[Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

BACKGROUND Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, binds to low-density lipoprotein (LDL) receptors, leading to their accelerated degradation and to increased LDL cholesterol levels. We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727). METHODS In healthy volunteers, we performed two randomized, sing...

متن کامل

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol

Received: 1 August 2015 Accepted: 29 September 2015 c © 2017 The Author(s), licensee Magdi Yacoub Institute. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY-4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. This article was originally published, as an unappr...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Atherosclerosis

سال: 2009

ISSN: 0021-9150

DOI: 10.1016/j.atherosclerosis.2008.03.009